Focus: Redona Therapeutics is a public biotech company focused on discovering and developing small molecules to target ncRNA biology, positioning itself in the emerging field of RNA-targeted therapeutics.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Redona Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Help build intelligence for Redona Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Redona Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer.
Kinetic and Mechanistic Studies of Human Oligoadenylate Synthetase 1.
Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins.
The SLAS Discovery Editor's Top 10 for 2022.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo